Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00044447
First received: August 28, 2002
Last updated: June 18, 2008
Last verified: June 2008
  Purpose

The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.


Condition Intervention Phase
Diabetes Mellitus, Non-Insulin-Dependent
Drug: Glimepiride
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change in HbA1C from baseline to Week 26.

Secondary Outcome Measures:
  • Incidence of hypoglycemia.

Enrollment: 170
Study Start Date: May 2001
Study Completion Date: September 2002
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have given their signed informed consent.
  • Males or females between 18 and 80 years old. Female patients must be surgically sterile, post-menopausal, or using an accepted method of birth control (i.e., oral contraceptives, intrauterine device, Norplant® system, Depo Provera®, or a spermicide and condom). Female patients of childbearing potential must have a negative serum pregnancy test and be advised not to become pregnant during the study.
  • At least 1 year history of NIDDM and performing home blood glucose monitoring.
  • Patients must have BMI of > 26 to < 42 kg/m2 at baseline (week 0).
  • Patients must have HbA1C > 7.5% but < 9.5% at screen (week -4).
  • Patients must have evidence of insulin secretory capacity (fasting C-peptide concentration > or equal to 0.27 nmol/l during the stabilization period).
  • Patients must have FPG > 130 mg/dl but < 235 mg/dl prior to (within 48-72 hours) randomization at Visit 1 Week 0.
  • Patients must be receiving as their current diabetic therapy stable doses of metformin (at dose of 1.0-2.5gm/day), or metformin extended release at a maximum dose of 2 gm/day and a half maximum to a maximum dose of thiazolidinedione for at least 3 months.
  • Patients must be able to understand and willing to adhere to and be compliant with the study protocol.

Exclusion Criteria:

  • Patients who require insulin therapy or are currently on other sulfonylureas.
  • Patients with a history of hypersensitivity to sulfonylureas.
  • Patients with past history of severe hypoglycemia reaction on their current antidiabetic therapy requiring medical attention.
  • Patients with a history of acute metabolic complications such as hyperosmolar coma or ketonuria.
  • Patients with clinically significant abnormal baseline laboratory values (hematology, blood chemistry or urinalysis) which define a disease or condition, which in the opinion of the investigator may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate and complete the study. Should there be a laboratory value which, upon initial screening, is substantially outside the normal range, the test should be repeated.
  • Patients who had an increase in their thiazolidinedione medication within 2 months of entering the study (Visit 0).
  • Patients who had an increase in the metformin medication within 1 month of entering the study (Visit 0).
  • Patients whose body weight has changed more than 2% for patients < 250 pounds or 3% for patients >= 250 pounds, during the 4 week stabilization period when compared to the weight at the screening visit 0 (week - 4).
  • Patients with acute infections.
  • Patients who have received any drug (i.e. a chemotherapy agent) with a well-defined potential for toxicity to a major organ system during the three months prior to the study.
  • Patients with clinically significant renal or hepatic disease (i.e. ALT > 2.5 x upper limit of normal) or gastrointestinal disorders that may interfere with absorption of the study drugs.
  • Patients who are allergic to sulfonamides and excipients.
  • Patients with any history of alcohol or drug abuse.
  • Pregnant or lactating females will be excluded.
  • Patients with a history of psychosis, emotional or intellectual problems that could impair the ability of the patient to participate in the study or to complete the study.
  • Patients who have participated in any investigational study within 30 days prior to Visit 0.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00044447

Locations
United States, Texas
Dallas Diabetes & Endocrine Center
Dallas, Texas, United States, 75230
Sponsors and Collaborators
Sanofi
Investigators
Study Director: ICD CSD Sanofi
  More Information

Additional Information:
No publications provided

Responsible Party: ICD Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00044447     History of Changes
Other Study ID Numbers: HOE490/4033
Study First Received: August 28, 2002
Last Updated: June 18, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Glimepiride
2,4-thiazolidinedione
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014